Compositions and methods for the therapy and diagnosis of influenza
The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.
1. An isolated fully human anti-matrix 2 ectodomain (M2e) antibody, where in the M2e is of an influenza A virus, and wherein said antibody comprises a VH CDR1 region comprising the amino acid sequence of NYYWS (SEQ ID NO: 72); a VH CDR2 region comprising the amino acid sequence of FIYYGGNTKYNPSLKS (SEQ ID NO: 74); a VH CDR3 region comprising the amino acid sequence of ASCSGGYCILD (SEQ ID NO: 76); a VL CDR1 region comprising the amino acid sequence of RASQNIYKYLN (SEQ ID NO: 59); a VL CDR2 region comprising the amino acid sequence of AASGLQS (SEQ ID NO: 61); and a VL CDR3 region comprising the amino acid sequence of QQSYSPPLT (SEQ ID NO: 63).
2. The antibody of claim 1 , wherein said antibody is isolated from a B-cell from a human donor.
3. An isolated anti-matrix 2 ectodomain (M2e) antibody, wherein the M2e is of an influenza A virus, and wherein said antibody comprises a V H CDR1 region comprising the amino acid sequence of NYYWS (SEQ ID NO: 72); a V H CDR2 region comprising the amino acid sequence of FIYYGGNTKYNPSLKS (SEQ ID NO: 74); a V H CDR3 region comprising the amino acid sequence of ASCSGGYCILD (SEQ ID NO: 76); a V L CDR1 region comprising the amino acid sequence of RASQNIYKYLN (SEQ ID NO: 59); a V L CDR2 region comprising the amino acid sequence of AASGLQS (SEQ ID NO: 61); and a V L CDR3 region comprising the amino acid sequence of QQSYSPPLT (SEQ ID NO: 63).
4. A composition comprising the antibody of claims 1 or 3 .
5. The composition of claim 4 , further comprising an anti-viral drug, a viral entry inhibitor or a viral attachment inhibitor.
6. The composition of claim 5 , wherein said anti-viral drug is a neuraminidase inhibitor, a HA inhibitor, a sialic acid inhibitor or an M2 ion channel inhibitor.
7. The method of claim 6 , wherein said M2 ion channel inhibitor is amantadine or rimantadine.
8. The method of claim 6 , wherein said neuraminidase inhibitor is zanamivir, or oseltamivir phosphate.
9. The composition of claim 4 , further comprising a second anti-influenza A antibody.
10. The antibody of claims 1 or 3 , wherein said antibody is operably-linked to a therapeutic agent or a detectable label.
11. A diagnostic kit comprising the antibody according to claims 1 or 3 .